MoonLake Immunotherapeutics (MLTX)
NASDAQ: MLTX · IEX Real-Time Price · USD
41.65
-0.78 (-1.84%)
Apr 25, 2024, 12:28 PM EDT - Market open
MLTX Stock Forecast
Stock Price Forecast
The 9 analysts with 12-month price forecasts for MLTX stock have an average target of 75, with a low estimate of 59 and a high estimate of 100. The average target predicts an increase of 80.07% from the current stock price of 41.65.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for MLTX stock from 10 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
---|---|---|---|---|---|---|
Strong Buy | 5 | 6 | 6 | 6 | 5 | 5 |
Buy | 2 | 2 | 2 | 3 | 3 | 3 |
Hold | 1 | 1 | 1 | 1 | 1 | 2 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 8 | 9 | 9 | 10 | 9 | 10 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $100 | Strong Buy | Reiterates | $100 | +140.10% | Apr 23, 2024 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $100 | Strong Buy | Reiterates | $100 | +140.10% | Apr 11, 2024 |
Needham | Needham | Strong Buy Reiterates $66 | Strong Buy | Reiterates | $66 | +58.46% | Apr 9, 2024 |
Goldman Sachs | Goldman Sachs | Hold Initiates $62 | Hold | Initiates | $62 | +48.86% | Apr 2, 2024 |
Wedbush | Wedbush | Buy Reiterates $92 | Buy | Reiterates | $92 | +120.89% | Mar 13, 2024 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-1.19
from -0.73
EPS Next Year
-1.81
from -1.19
Revenue Forecast
Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | n/a | n/a | n/a | 220.5M | 1.0B |
Avg | n/a | n/a | n/a | 114.3M | 570.2M |
Low | n/a | n/a | n/a | 55.7M | 249.7M |
Revenue Growth
Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | - | - | - | - | 804.6% |
Avg | - | - | - | - | 398.9% |
Low | - | - | - | - | 118.5% |
EPS Forecast
EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | -0.55 | -0.73 | -0.76 | -2.34 | 2.95 |
Avg | -1.19 | -1.81 | -2.54 | -2.27 | 2.87 |
Low | -1.89 | -2.81 | -4.41 | -2.19 | 2.75 |
EPS Growth
EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | - | - | - | - | - |
Avg | - | - | - | - | - |
Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.